Breaking News Instant updates and real-time market news.

CNCE

Concert Pharmaceuticals

$5.85

(0.00%)

15:29
10/13/19
10/13
15:29
10/13/19
15:29

Concert Pharmaceuticals presents Phase 2 data in Alopecia Areata

Concert Pharmaceuticals presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. Patients in the study treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p less than0.001) relative to placebo in the percentage of patients achieving a greater than or equal to 50% relative change from baseline at 24 weeks using the Severity of Alopecia Tool. In the Phase 2 trial, the primary efficacy endpoint in the 12 mg twice-daily cohort was met with 58% of patients achieving a greater than or equal to 50% relative reduction in their overall SALT score from baseline compared to 9% for placebo, with statistically significant separation from placebo occurring at Week 12. In the 8 mg twice-daily cohort, 47% of patients achieved the primary endpoint compared to placebo. For the 4 mg cohort, 21% of patients achieved a greater than or equal to 50% relative reduction in their overall SALT score from baseline, however there was not a statistically significant difference from placebo. Data from the Patient Global Impression of Improvement scale showed 78% of the patients receiving 12 mg twice-daily and 58% of the patients receiving 8 mg twice-daily rated their alopecia areata as "much improved" or "very much improved" at Week 24. For both doses there was a statistically significant difference from placebo. In the Phase 2 trial, the most common side effects in the 12 mg CTP-543 dose group were headache, nasopharyngitis, upper respiratory tract infection and acne. One serious adverse event of facial cellulitis was reported as possibly related to treatment. After a brief dosing interruption, treatment was continued and this patient completed the trial. No thromboembolic events were reported during the trial.

CNCE Concert Pharmaceuticals
$5.85

(0.00%)

09/30/19
MZHO
09/30/19
NO CHANGE
Target $18
MZHO
Buy
Concert Pharmaceuticals price target lowered to $18 from $29 at Mizuho
Mizuho analyst Difei Yang lowered her price target for Concert Pharmaceuticals to $18 from $29 after the company's partner Avanir on Friday reported negative top-line results from the second Phase 3 study of AVP-786 for the treatment of moderate-to-severe Alzheimer's agitation. The analyst no longer takes into account the AVP-786 program into Concert's valuation. However, she continues to believe Concert's CTP-543 has the potential of being best in case for treating Alopecia Areata, and she notes the company has about $6 per share in cash. Yang reiterates a Buy rating on Concert Pharmaceuticals.
09/30/19
RHCO
09/30/19
NO CHANGE
Target $20
RHCO
Buy
Concert Pharmaceuticals price target lowered to $20 from $30 at SunTrust
SunTrust analyst Joon Lee lowered his price target on Concert Pharmaceuticals to $20 after the company's partner Avanir disclosed negative top-line results from the second Phase 3 study of AVP-786 for the treatment of moderate-to-severe Alzheimer's agitation. The analyst is removing the Alzheimer's agitation potential from his valuation model but maintains his Buy rating on the stock, citing the company's "best-in-class" alopecia areata data for CTP-543 and the expected start of phase 2 trial of its CTP-692 in Q4 of this year.
10/02/19
MZHO
10/02/19
NO CHANGE
Target $18
MZHO
Buy
Concert Pharmaceuticals shares offer 'significant value,' says Mizuho
Concert Pharmaceuticals shares have continued to sell off following last week's negative AVP-786 data and currently trade near the company's cash value of $5, Mizuho analyst Difei Yang tells investors in a research note. The analyst, however, continues to see "significant value" in Concert's clinical pipeline. CTP-543 remains a key value driver, and earlier-stage asset CTP-692, for the adjunctive treatment of schizophrenia, is set to enter Phase 2 in Q4 and offers additional potential upside, says Yang. The analyst reiterates a Buy rating on Concert Pharmaceuticals.
10/03/19
HCWC
10/03/19
NO CHANGE
Target $25
HCWC
Buy
Concert selloff brings attractive entry point, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered his price target for Concert Pharmaceuticals to $25 from $29 following the miss of the second Phase 3 clinical study of AVP-786 for the treatment of moderate-to-severe agitation in patients with Alzheimer's disease. However, even in the absence of this partnered asset, Concert's two clinical programs, namely CTP-543 for alopecia areata and CTP-692 for schizophrenia, are sufficient to drive the fundamental value of the company, Fein tells investors in a research note. As such, he thinks the recent stock pullback may create an attractive entry point for investors to capture the value of these two programs. The analyst reiterates a Buy rating on Concert Pharmaceuticals.

TODAY'S FREE FLY STORIES

TRPX

Therapix Biosciences

$1.50

-0.13 (-7.98%)

17:49
11/20/19
11/20
17:49
11/20/19
17:49
Hot Stocks
Therapix Biosciences to appeal Nasdaq delisting notice »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$117.84

4.43 (3.91%)

17:47
11/20/19
11/20
17:47
11/20/19
17:47
Recommendations
Lowe's analyst commentary  »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

NDAQ

Nasdaq

$105.68

0.52 (0.49%)

17:39
11/20/19
11/20
17:39
11/20/19
17:39
Periodicals
Nasdaq executive Nelson Griggs sees fewer IPOs in 2020, Bloomberg says »

Nelson Griggs, executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$57.91

-0.46 (-0.79%)

17:37
11/20/19
11/20
17:37
11/20/19
17:37
Hot Stocks
Intel acknowledges PC CPU shipment delays in letter »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

  • 23

    Jan

AAPL

Apple

$263.19

-3.13 (-1.18%)

, SPX

S&P 500

$0.00

(0.00%)

17:35
11/20/19
11/20
17:35
11/20/19
17:35
Periodicals
Trump says considering whether to exempt Apple from China tariffs, Reuters says »

U.S. President Donald…

AAPL

Apple

$263.19

-3.13 (-1.18%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$310.82

-1.07 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$216.91

-1.26 (-0.58%)

17:28
11/20/19
11/20
17:28
11/20/19
17:28
Hot Stocks
Raytheon awarded $386M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLH

Red Lion Hotels

$3.36

0.015 (0.45%)

17:23
11/20/19
11/20
17:23
11/20/19
17:23
Syndicate
Breaking Syndicate news story on Red Lion Hotels »

Red Lion Hotels files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KZIA

Kazia Therapeutics

$7.40

4 (117.65%)

17:20
11/20/19
11/20
17:20
11/20/19
17:20
Hot Stocks
Breaking Hot Stocks news story on Kazia Therapeutics »

Kazia Therapeutics Ltd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$30.05

0.13 (0.43%)

17:14
11/20/19
11/20
17:14
11/20/19
17:14
Syndicate
Invitation Homes announces offering of 57.6M shares of common stock for holders »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UVV

Universal Corporation

$50.73

-0.84 (-1.63%)

17:08
11/20/19
11/20
17:08
11/20/19
17:08
Hot Stocks
Universal Corporation to acquire FruitSmart, terms not stated »

Universal Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$28.02

0.99 (3.66%)

17:06
11/20/19
11/20
17:06
11/20/19
17:06
Hot Stocks
Breaking Hot Stocks news story on Uber »

Uber up 2.1% or 59c at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

SBLK

Star Bulk Carriers

$10.04

-0.12 (-1.18%)

17:03
11/20/19
11/20
17:03
11/20/19
17:03
Earnings
Star Bulk Carriers reports Q3 EPS 18c, two estimates 17c »

Reports Q3 voyage revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

KRNY

Kearny Financial

$14.11

-0.08 (-0.56%)

17:01
11/20/19
11/20
17:01
11/20/19
17:01
Hot Stocks
Kearny Financial raises quarterly dividend to 7c from 6c per share »

Payable on December 20 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$16.00

-1.19 (-6.92%)

16:48
11/20/19
11/20
16:48
11/20/19
16:48
Hot Stocks
Breaking Hot Stocks news story on L Brands »

L Brands up 5.8% or 92c…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

LVMUY

LVMH

$0.00

(0.00%)

, TIF

Tiffany

$123.32

-0.16 (-0.13%)

16:47
11/20/19
11/20
16:47
11/20/19
16:47
Periodicals
LVMH, Tiffany said to be in talks, Bloomberg says »

LVMH (LVMUY) is said to…

LVMUY

LVMH

$0.00

(0.00%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

LB

L Brands

$16.00

-1.19 (-6.92%)

16:46
11/20/19
11/20
16:46
11/20/19
16:46
Hot Stocks
L Brands backs FY19 free cash flow forecast at ~$750M »

Cuts FY19 SSS view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

UBER

Uber

$28.02

0.99 (3.66%)

16:43
11/20/19
11/20
16:43
11/20/19
16:43
Hot Stocks
Uber CEO Dara Khosrowshahi buys almost $7M in company shares »

Uber CEO Dara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

AVVIY

Aviva

$0.00

(0.00%)

16:42
11/20/19
11/20
16:42
11/20/19
16:42
Downgrade
Aviva rating change  »

Aviva downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLLGY

Hella KGaA Hueck

$0.00

(0.00%)

16:42
11/20/19
11/20
16:42
11/20/19
16:42
Upgrade
Hella KGaA Hueck rating change  »

Hella GmbH upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEG

Key Energy

$0.30

0.0095 (3.32%)

16:40
11/20/19
11/20
16:40
11/20/19
16:40
Hot Stocks
Key Energy receives notice from NYSE regarding continued listing requirements »

Key Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLLGY

Hella KGaA Hueck

$0.00

(0.00%)

16:40
11/20/19
11/20
16:40
11/20/19
16:40
Upgrade
Hella KGaA Hueck rating change  »

Hella KGaA Hueck upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGHC

National General

$20.47

-0.43 (-2.06%)

16:39
11/20/19
11/20
16:39
11/20/19
16:39
Hot Stocks
National General approved to sell its Accident Health and Care Sweden unit »

National General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$126.37

15.51 (13.99%)

, LOW

Lowe's

$117.84

4.43 (3.91%)

16:38
11/20/19
11/20
16:38
11/20/19
16:38
On The Fly
Fly Intel: Wall Street's top stories for Wednesday »

Stocks were slumping a…

TGT

Target

$126.37

15.51 (13.99%)

LOW

Lowe's

$117.84

4.43 (3.91%)

GM

General Motors

$35.26

-1.13 (-3.11%)

FCAU

Fiat Chrysler

$15.00

-0.585 (-3.75%)

KNSA

Kiniksa

$8.95

1.97 (28.22%)

ALNY

Alnylam

$108.26

10.27 (10.48%)

URBN

Urban Outfitters

$24.41

-4.32 (-15.04%)

PDD

Pinduoduo

$31.37

-9.34 (-22.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 03

    Dec

  • 05

    Dec

  • 07

    Dec

  • 04

    Feb

TUWOY

Tullow Oil

$0.00

(0.00%)

16:37
11/20/19
11/20
16:37
11/20/19
16:37
Downgrade
Tullow Oil rating change  »

Tullow Oil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKL

Markel

$1,126.21

1.26 (0.11%)

16:36
11/20/19
11/20
16:36
11/20/19
16:36
Hot Stocks
Markel executive chairman Alan Kirshner to retire »

Markel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.